Alnylam Pharmaceuticals (ALNY) Beats Q4 Earnings and Revenue Estimates

Company Performance - Alnylam Pharmaceuticals reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of a loss of$ 0.21 per share, and showing improvement from a loss of $1.10 per share a year ago, resulting in an earnings surprise of 128.57% [1] - The company achieved revenues of$ 593.17 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 4.05%, compared to revenues of $439.72 million in the same quarter last year [2] - Over the last four quarters, Alnylam has surpassed consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2] Stock Outlook - Alnylam shares have increased approximately 13% since the beginning of the year, outperforming the S&P 500's gain of 2.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$ 0.52 on revenues of $523.19 million, while for the current fiscal year, the estimate is$ 0.41 on revenues of $2.51 billion [7] - The estimate revisions trend for Alnylam is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - Alnylam operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]